Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

@article{Yazbeck2009DipeptidylPI,
  title={Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?},
  author={Roger Yazbeck and Gordon Stanley Howarth and Catherine A Abbott},
  journal={Trends in pharmacological sciences},
  year={2009},
  volume={30 11},
  pages={600-7}
}
Dipeptidyl peptidase (DPP)-4 is a member of the S9b serine protease family, which also includes DPP8 and DPP9. DPP4 cleaves a number of regulatory factors, including chemokines and growth factors. DPP4 inhibitors have recently emerged as an effective treatment option for type 2 diabetes. Early in vitro studies demonstrated that DPP4 inhibitors inhibit T-cell proliferation and cytokine production, leading to their investigation in numerous pre-clinical models of inflammatory diseases, including… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS